Nuovi farmaci antidiabete e ipogonadismo maschile

Hypogonadotropic hypogonadism is frequently observed in people with type 2 diabetes mellitus. Central obesity and metabolic syndrome play a crucial role in the development of hypogonadism, and the newest drugs used for the treatment of type 2 diabetes, in particular GLP-1 RAs, showed a possible therapeutic role in this condition. SGLT2i and the new GLP-1 RA/GIP associations have demonstrated benefits on some of the multiple mechanisms involved in the pathophysiology of hypogonadism linked to obesity and type 2 diabetes too, representing a thriving field of research.